Clinical Trial

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

Study acronym: RIO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
RIO is a placebo-controlled double-blinded two arm prospective phase II randomised controlled trial . This study will test the use of broadly neutralising antibodies (bNAbs) in participants with treated primary HIV infection (PHI).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-03-20; most recent amendment 2024-04-16.
Status change: Not Yet Recruiting → Recruiting 2021-07-05
Trial Details
NCT Number NCT04319367
Lead Sponsor Imperial College London
Collaborators: Bill and Melinda Gates Foundation, University of Oxford, Rockefeller University
Conditions HIV/AIDS and Infections
Enrollment 72 participants
Start Date 2021-05-17
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-17